About DILIsym Services, Inc., a Simulations Plus company

DILIsym Services, Inc. was incorporated in 2014 and operates in Research Triangle Park, North Carolina. DILIsym Services, Inc. is committed to providing the pharmaceutical industry with the tools, resources and information to more efficiently develop safe and effective drug therapies that increase the availability of vital therapeutics for the patients who need them.  DILIsym Services, Inc. has developed the DILIsym® modeling software and the NAFLDsym® modeling software to support these objectives.  DILIsym Services, Inc. makes this software available to pharmaceutical companies in addition to performing services projects with the modeling software.  In these projects, the DILIsym Services, Inc. expert scientific team engages clients from initial program design through data input and results interpretation.

Our mission is to help ensure the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury, metabolic diseases, and modeling and simulation. We aim to make drug development more efficient for the pharmaceutical industry by informing key decisions, which will in turn lead to increased availability of vital medicines for the patients who need them.

DILIsym® Services may be utilized by companies involved in the research and development of drugs or chemicals, including services such as conducting simulations of drug-liver interactions, and designing computer software for companies to be used in modeling liver responses to a drug or chemical.

Our Goals

DILIsym Services, Inc. has the overarching goal of applying the DILIsym software to improve the safety profiles of therapeutics reaching the market. To achieve this goal, three significant objectives have been developed:

  • Inform and impact the candidate selection process for therapeutic development teams in the preclinical development space as they prioritize the progression of compounds not yet taken into man;
  • Provide information regarding the risk aspect of the risk versus benefit question often debated as large investments are considered to progress compounds from early stage clinical development to later stage, larger trials;
  • Identify and/or substantiate precision medicine approaches from a safety perspective that may allow therapeutics to reach a majority of the target patient population without harming a few.
A woman stands confidently, embodying the precision of ADMET Predictor™ PBPK modeling.
A woman stands confidently, embodying the precision of ADMET Predictor™ PBPK modeling.
Our Software

DSSI has multiple software platforms to support biotechnology and pharmaceutical companies in the development of safe and effective treatments. These software platforms support DILI-sim Initiative and DSSI goals of improving patient safety, reducing the need for animal testing, and reducing the costs and time necessary to develop new drugs. Click on the software submodules titles on the right hand to learn more.

RENAsym is quantitative systems toxicology (QST) software for predicting and understand drug-induced kidney injury with the use of mechanistic, mathematical modeling to predict whether new drug candidates will cause renal injury signals in patients and to enhance the understanding of mechanisms that contribute to renal safety signals already observed in the clinic.

NAFLDsym modeling software is a mechanistic, mathematical model of nonalcoholic fatty liver disease (NAFLD), which can be used to predict efficacy for treatment modalities developed for NAFLD and nonalcoholic steatohepatitis (NASH).

The ILDsym QSP modeling software is a mechanistic, mathematical model of interstitial lung disease (ILD) associated with systemic sclerosis (SSc). ILDsym can be used to predict efficacy for treatment modalities developed for SSc-ILD (and other interstitial lung diseases with custom modifications and additions).

The IPFsym® QSP modeling software is a mechanistic, mathematical model of idiopathic pulmonary fibrosis (IPF). IPFsym can be used to predict efficacy for treatment modalities developed for IPF (and other lung diseases with custom modifications and additions).

The DILI-sim Initiative

The DILI-sim Initiative is a consortium of life science companies led by DILIsym Services, Inc. and charged with developing DILIsym software, a predictive, mathematical model of drug-induced liver injury. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs. DILI-sim is currently welcoming new members. Perhaps most importantly, DILI-sim members have a prevailing voice in the development plan of the DILIsym software, ensuring that the model will be of maximum utility as it is developed within their respective organizations. Members also get the chance to hear and learn from one another at regular virtual and face to face meetings, where scientific discussions centered around DILI occur.

The DILI-sim Initiative
Membership Login
Login
View QSP/QST Workshops
learn more
Applications of DILIsym Services® products
Peer-reviewed Publications
view all publications